Skip to content
Life Sciences Series C Founded 2017

ChosenMed

Provider of a wide range of genomic services. The company offers gene detection services (diagnosis, prognosis, and recurrence monitoring) for diseases like acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome (MDS), myeloproliferative tumor, genetic testing of blood tumors. Founded in 2017, headquartered in Jinghai, China. The company has raised $14.1M in funding at the series c stage. The…

📍 Jinghai, China · Genomics,

Funding snapshot

Last roundSeries C
Amount$14M
Date20 December 2021
Total raised$14M
Team size4

About

Provider of a wide range of genomic services. The company offers gene detection services (diagnosis, prognosis, and recurrence monitoring) for diseases like acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome (MDS), myeloproliferative tumor, genetic testing of blood tumors. Founded in 2017, headquartered in Jinghai, China. The company has raised $14.1M in funding at the series c stage. The team comprises 4 (Jun 30, 2026) employees. Backed by investors including Shangha Founded in 2017, headquartered in Jinghai, China, the company has raised $14.1M in Series C funding. The company operates in the Life Sciences sector. Its business model encompasses Genomics. The company leverages advanced technology to address market needs and deliver innovative solutions to its target customers.

Business model

Genomics > Genomics Services > Sequencing,

Life Sciences Platforms and Tools > Research Services > Genomics

Institutional investors

Shanghai Alliance Financial Services heyahuayi.com HLC Medfine Capital Delta Capital Yijing Capital Gaoxin Kangyang Jingming Capital Mifang Capital Xiamen Qianshan Yunfan Asset Management

Latest coverage

No articles yet.

Raising like ChosenMed?

Analyze your pitch deck before your next raise.

Analyze My Deck →